HIV-infected individuals are at increased risk of neurocognitive impairment compared to the general population. Studies suggest that, despite combination antiretroviral therapy (cART), HIV infection causes immune activation which results in neural damage; however, few data exist in HIV-infected youth.
Methods
HIV-infected youth 8–26-years-old on cART with virological suppression were prospectively enrolled along with healthy controls. Neurocognitive performance was assessed by age-appropriate Wechsler Intelligence Scales. Soluble and cellular markers of T-lymphocyte and monocyte activation were measured by ELISA and flow cytometry, respectively.
Results
45 HIV-infected subjects and 21 controls were enrolled. Markers of T-cell and monocyte activation were higher in the HIV-infected subjects compared to controls, but proportions of inflammatory and patrolling monocytes were similar. Although there were no significant differences in neurocognitive scores between the HIV-infected and control groups, scores were low-average for four of five testing domains for the HIV-infected subjects and average for all five in the controls, and % of HIV-infected subjects with scores classified as ‘low average’ or below was higher than in the controls. Variables most associated with neurocognitive performance among HIV-infected subjects included activated CD4+ T-cells (% CD4+CD38+HLA-DR), monocyte activation (soluble CD14), HIV duration, age and sex.
Conclusions
HIV-infected youth on cART with virological suppression show subtle evidence of neurocognitive impairment compared to healthy controls, and increased immune activation appears to play a role. Additional studies are needed to develop strategic interventions beyond cART to potentially improve neurocognitive performance and/or minimize further impairment in this vulnerable population. ClinicalTrials.gov Identifier: NCT01523496.
References
1.
Van RieA.H.P., DowA., RobertsonK.Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective.Eur J Paediatr Neuro2007; 11: 1–9.
2.
LetendreS.Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.Top Antivir Med2011; 19: 137–142.
3.
SchoutenJ., CinqueP., GisslenM., ReissP., PortegiesP.HIV-1 infection and cognitive impairment in the cART era: a review.AIDS2011; 25: 561–575.
4.
DrotarD., OlnessK., WiznitzerM.Neurodevelopmental outcomes of Ugandan infants with HIV infection: an application of growth curve analysis.Health Psychol1999; 18: 114–121.
5.
GayC.L., ArmstrongF.D., CohenD.The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months.Pediatrics1995; 96: 1078–1082.
6.
KnightW.G., MellinsC.A., LevensonR.L.Jr., ArpadiS.M., KairamR.Brief report: effects of pediatric HIV infection on mental and psychomotor development.J Pediatr Psychol2000; 25: 583–587.
7.
KoekkoekS., de SonnevilleL.M., WolfsT.F., LichtR., GeelenS.P.Neurocognitive function profile in HIV-infected school-age children.Eur J Paediatr Neuro2008; 12: 290–297.
8.
AllenA.B.J.M., ForsythB.Pediatric HIV/AIDS. In: DavisA., ed. The Handbook of Pediatric Neuropsychology. New York: Springer Publishing Company, LLC 2011, pp. 865–876.
TardieuM., MayauxM.J., SeibelN.Cognitive assessment of school-age children infected with maternally transmitted human immunodeficiency virus type 1.J Pediatr1995; 126: 375–379.
11.
HavensJ., WhitakerA., FeldmanJ., AlvaradoL., EhrhardtA.A controlled study of cognitive and language function in school-aged HIV-infected children.Ann N Y Acad Sci1993; 693: 249–251.
12.
LlorenteA.M.L.C., SatzP.Neurobehavioral and neurodevelopmental sequelae associated with pediatric HIV infection. In: ReynoldsC.R. F-J.E., ed. Handbook of Clinical Child Neuropsychology. Third ed. New York: Springer Publishing Company, LLC 2009, pp. 635–669.
13.
RumbaughJ.A., SteinerJ., SacktorN., NathA.Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.Futur HIV Ther2008; 2: 271–280.
14.
SimioniS., CavassiniM., AnnoniJ.M.Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.AIDS2010; 24: 1243–1250.
15.
RobertsonK.R., SmurzynskiM., ParsonsT.D.The prevalence and incidence of neurocognitive impairment in the HAART era.AIDS2007; 21: 1915–1921.
16.
HeatonR.K., FranklinD.R., EllisR.J.HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.J Neurovirol2011; 17: 3–16.
17.
EllisR.J., CaleroP., StockinM.D.HIV infection and the central nervous system: a primer.Neuropsychol Rev2009; 19: 144–151.
18.
ValcourV., SithinamsuwanP., LetendreS., AncesB.Pathogenesis of HIV in the central nervous system.Curr HIV/AIDS Rep2011; 8: 54–61.
19.
GrasG., KaulM.Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection.Retrovirology2010; 7: 30.
20.
LambotteO., TaoufikY., de GoerM.G., WallonC., GoujardC., DelfraissyJ.F.Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy.J Acquir Immune Defic Syndr2000; 23: 114–119.
21.
KapetanovicS., LeisterE., NicholsS.Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth.AIDS2010; 24: 1481–1491.
22.
KaulM., LiptonS.A.Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS.J Neuroimmune Pharmacol2006; 1: 138–151.
23.
Fischer-SmithT., CroulS., SverstiukA.E.CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection.J Neurovirol2001; 7: 528–541.
24.
KhayatD., SoubraneC., AndrieuJ.M.Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors.J Infect Dis1990; 161: 430–435.
25.
LyonsJ.L., UnoH., AncutaP.Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection.J Acquir Immune Defic Syndr2011; 57: 371–379.
26.
PulliamL., GasconR., StubblebineM., McGuireD., McGrathM.S.Unique monocyte subset in patients with AIDS dementia.Lancet1997; 349: 692–695.
27.
KamatA., LyonsJ.L., MisraV.Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.J Acquir Immune Defic Syndr2012; 60: 234–243.
28.
KamatA., MisraV., CassolE.A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.PLoS One2012; 7: e30881.
29.
MarcotteT.D., DeutschR., MichaelB.D.A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.J Neuroimmune Pharmacol2013; 8: 1123–1135.
30.
LebelC., BeaulieuC.Longitudinal development of human brain wiring continues from childhood into adulthood.J Neurosci2011; 31: 10937–10947.
31.
KapetanovicS., GrinerR., ZeldowB.Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysis.AIDS2014; 28: 355–364.
32.
KapetanovicS., AaronL., MontepiedraG., BurchettS.K., KovacsA.T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children.AIDS2012; 26: 959–969.
33.
WechslerD.WAIS-IV Administration and Scoring Manual.San Antonio: The Psychological Corporation; 2008a.
34.
WechslerD.WAIS-IV Technical and Interpretive Manual.San Antonio: The Psychological Corporation; 2008b.
ShiramizuB., AnanworanichJ., ChalermchaiT.Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy.J Neurovirol2012; 18: 69–73.
38.
AnanworanichJ., KerrS.J., JaimulwongT.Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children.Journal of Virus Eradication2015; 1: 196–202.
39.
GrauerO.M., ReicheltD., GrunebergU.Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.Ann Clin Transl Neurol2015; 2: 906–919.
40.
VassalloM., DurantJ., Lebrun-FrenayC.Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.HIV Med2015; 16: 431–440.
41.
BrewB.J., LetendreS.L.Biomarkers of HIV related central nervous system disease.Int Rev Psychiatry2008; 20: 73–88.
42.
Ziegler-HeitbrockL.The CD14+ CD16+ blood monocytes: their role in infection and inflammation.J Leukoc Biol2007; 81: 584–592.
43.
BhaskaranK., MussiniC., AntinoriA.Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.Ann Neurol2008; 63: 213–221.
44.
CraneN.A., SchusterR.M., GonzalezR.Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users.J Int Neuropsychol Soc2013; 19: 1009–1015.
45.
DoughertyD.M., MathiasC.W., DawesM.A.Impulsivity, attention, memory, and decision-making among adolescent marijuana users.Psychopharmacology (Berl)2013; 226: 307–319.
MolinaP.E., WinsauerP., ZhangP.Cannabinoid administration attenuates the progression of simian immunodeficiency virus.AIDS Res Hum Retroviruses2011; 27: 585–592.
48.
PetersonP.K., GekkerG., HuS., CabralG., LokensgardJ.R.Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures.J Neuroimmunol2004; 147: 123–126.
49.
RomS., PersidskyY.Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.J Neuroimmune Pharmacol2013; 8: 608–620.
50.
KimH.J., ShinA.H., ThayerS.A.Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss.Mol Pharmacol2011; 80: 357–366.
51.
LutgeE., GrayA., SiegfriedN.The medical use of cannabis for reducing morbidity and mortality in patients with HIV/ AIDS.Cochrane Database Syst Rev2013; CD005175.
